Women with a primary breast cancer (PBC) diagnosis and a pathogenic germline mutation in the BRCA1 or BRCA2 gene are at increased risk of developing metachronous contralateral breast cancer (CBC). The gene discussed is BRCA1; the disease is complete blood cell count.